期刊文献+

ISA720与CpG联合佐剂增强恶性疟原虫抗原的免疫原性 被引量:1

Enhancement of immunogenicity of Plasmodium falciparum antigens by combination of CpG ODN protein with montanide ISA720 adjuvant
原文传递
导出
摘要 目的评价CpG佐剂对以PfCP-2.9/ISA720佐剂为基础的联合疟疾抗原的免疫原性。方法使用ISA720及ISA720+CpG佐剂与恶性疟原虫抗原制备制剂,免疫BALB/c小鼠,考察不同佐剂增强免疫的效果。通过检测免疫血清中特异性IgG的水平、识别天然抗原的能力、分析特异性IgG的亚类分布等指标进行评价。结果 CpG佐剂显著提升了联合疟疾抗原在BALB/c小鼠中产生特异性抗体的量(P<0.01),免疫血清能有效识别红内期疟原虫天然抗原,IFA滴度显著提高(P<0.01),IgG亚类分析显示该佐剂能有效刺激小鼠产生针对PfCP-2.9和Pfclet-3的多种IgG亚类抗体。结论 CpG显著提高了联合疟疾抗原的免疫原性。 Aim To evaluate the effect of combination of CpG ODN with montanide ISA720 adjuvant on immunogenieity of a multistage malaria antigen. Methods BALB/c mice were separately immunized by PfCP-2.9 and Pfclet-3 proteins formulated with ISA720 or ISA720 +CpG adjuvant. The specific antibody levels of immunized sera, interaction of specific antibodies with native parasite antigens and the IgG subclass category were determined. Result Compared with ISA720 groups,the addition of CpG ODN significantly promoted the specific antibody levels against both antigens in BALB/e mice model(P〈0.01 ),and improved the interaction of specific antibodies with native parasite antigens(P〈 0.01 ). There the levels of four IgG subclasses were induced in the mice immunized by the formulation containing antigens and ISA720+CpG adjuvants. Conclusion CpG ODN significantly improved the immunogenieity of multistage combination malaria antigens.
出处 《中国热带医学》 CAS 2010年第7期786-788,共3页 China Tropical Medicine
关键词 恶性疟原虫 抗原 佐剂 IGG亚型 Plasmodium falciparum Antigen Adjuvant IgG isotype
  • 相关文献

参考文献16

  • 1Thera MA,Doumbo OK,Coulibaly D,et al. Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial [J] . PLoS One,2010,5(2):e9041.
  • 2Ellis RD,Martin LB,Shaffer D,et al . Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1 (42)-C1/Alhydrogel with and without CPG 7909 in malaria nave adults [J] . PLoS One,2010,5 ( 1 ) : e8787.
  • 3Patarroyo ME,Patarroyo MA . Emerging rules for subunit-based,muhiantigenic,muhistage chemically synthesized vaccines [J] . Ace Chem Res, 2008,41 ( 3 ) : 377-386.
  • 4Pan W,Huang D,Zhang Q,et al . Fusion of two malaria vaccine candidate antigens enhances product yield,immunogenicity,and antibody-mediated inhibition of parasite growth in vitro [J] . J Immunol, 2004,172(10) : 6167-6174.
  • 5Peng H,Hu YF,Zhou Aiguo,et al . Solution structure of a Plasmodium falciparum AMA-1/MSP 1 chimeric protein vaccine candidate ( PfC P-2.9 ) for malaria [ J ] . Malaria Journal, 201 O, 9 : 76.
  • 6Malkin E,Hu J,Li Z,et al . A phase 1 trial of PfCP'2.9: an AMAI/ MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria [J] . Vaccine,2008,26(52):6864-6873.
  • 7Hu J,Chen Z,Gu J,et al . Safety and immunogenicity of a malaria vaccine,Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults [J] . PLoS One, 2008,3(4) :e1952.
  • 8Zhang Q,Xue X,Qu L,et al . Construction and evaluation of a muhistage combination vaccine against malaria [J] . Vaccine, 2007,25(11):2112-2119.
  • 9Wizel B, Houghten R, Church P, et al . HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunlzed volunteers [J] . J Immunol, 1995,155 (2) : 766-775.
  • 10Mullen GE,Giersing BK,Ajose-Popoola O,et al . Enhancement of functional antibody responses to AMA 1 -C1/Alhydrogel,a Plasmodium falciparum malaria vaccine,with CpG oligodeoxynucleotide[J] . Vaccine, 2006,24(14) : 2497-2505.

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部